| Name | Title | Contact Details |
|---|
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has four product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome. GCS-100 is La Jolla’s first-in-class galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010, La Jolla’s second-generation galectin-3 inhibitor, is a more potent and purified derivative of GCS-100 that can be delivered orally for the potential treatment of nonalcoholic steatohepatitis and other diseases characterized by tissue fibrosis. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hemochromatosis and beta thalassemia
We design affordable, safe and effective drugs to safeguard and empower the brain throughout all stages of life. Our aim is to improve quality of life and longevity.
Global Pharmaceutical Corp is a Chalfont, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Inotiv: (bio)analytical, in vivo, toxicology and molecular pathology services for preclinical drug metabolism in drug development.
Avadim Health is a life sciences company that offers advanced, safe solutions in everything from immune health to neuromuscular care. They are committed to helping those in need benefit from their products and have a strong pipeline across a broad rang...